OSL — Oncosil Medical Share Price
0.000.00%
Last trade - 00:00- AU$27.94m
- AU$23.15m
- AU$0.43m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 0.51 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.8 | ||
| Price to Tang. Book | 3.8 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 43.68 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -277.74% | ||
| Return on Equity | -237.87% | ||
| Operating Margin | -3247.96% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 3.83 | 2.87 | 1.38 | 1.07 | 0.43 | 4.82 | 13.86 | -37.72% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
OncoSil Medical Ltd is an Australia-based medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer (LAPC). The Company is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The Company has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.
Directors
- Otto Buttula NEC
- Nigel Lange CEO
- Karl Pechmann CFO
- Ralph Peters OTH
- David Turner OTH
- Martin Cross DRC
- Daniel Kenny DRC
- Ricky Sharma NED
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 14th, 2005
- Public Since
- August 15th, 2005
- No. of Shareholders
- 4,708
- No. of Employees
- 2
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 3,103,954,978
- Address
- Suite 503, Level 5, 15 Blue Street, NORTH SYDNEY, 2060
- Web
- http://www.oncosil.com.au/
- Phone
- +61 292233344
- Auditors
- Crowe Sydney
Upcoming Events for OSL
Oncosil Medical Ltd Annual Shareholders Meeting
Similar to OSL
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
FAQ
What is the Oncosil Medical share price?
As of Today at 10:30 UTC, shares in Oncosil Medical are trading at AU$0.01. This share price information is delayed by 15 minutes.
How has the Oncosil Medical share price performed this year?
Shares in Oncosil Medical last closed at AU$0.01 and the price had moved by -61.54% over the past 365 days. In terms of relative price strength the Oncosil Medical share price has underperformed the ASX All Ordinaries Index by -64.97% over the past year.
What are the analyst and broker recommendations for Oncosil Medical?
The overall consensus recommendation for Oncosil Medical is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Oncosil Medical dividend yield?
Oncosil Medical does not currently pay a dividend.
Does Oncosil Medical pay a dividend?
Oncosil Medical does not currently pay a dividend.
When does Oncosil Medical next pay dividends?
Oncosil Medical does not currently pay a dividend.
How do I buy Oncosil Medical shares?
To buy shares in Oncosil Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Oncosil Medical?
As of the previous close price of AU$0.01, shares in Oncosil Medical had a market capitalisation of AU$15.52m.
Where are Oncosil Medical shares listed?
Here are the trading details for Oncosil Medical:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: OSL
What kind of share is Oncosil Medical?
Based on an overall assessment of its quality, value and momentum Oncosil Medical is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Oncosil Medical share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Oncosil Medical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oncosil Medical. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -45.69%.
As of the last closing price of AU$0.01, shares in Oncosil Medical were trading -35.37% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Oncosil Medical PE Ratio?
The Oncosil Medical PE ratio based on its reported earnings over the past 12 months is 0.51. The shares last closed at AU$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Oncosil Medical?
Oncosil Medical's management team is headed by:
- Otto Buttula - NEC
- Nigel Lange - CEO
- Karl Pechmann - CFO
- Ralph Peters - OTH
- David Turner - OTH
- Martin Cross - DRC
- Daniel Kenny - DRC
- Ricky Sharma - NED